Article
Favipiravir-resistant influenza A virus shows potential for transmission
1 Jun 2021
Abstract excerpt
Favipiravir is a nucleoside analogue which has been licensed to treat influenza in the event of a new pandemic. We previously described a favipiravir resistant influenza A virus generated by in vitro passage in presence of drug with two mutations: K229R in PB1, which conferred resistance at a cost to polymerase activity, and P653L in PA, which compensated for the cost of polymerase activity. However, the clinical...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.
